3 months was attained by 35.6% (379 patients). Prior statin use was not associated with increased odds for sICH (OR 1.05, 95% CI 0.55-2.04, p = 0.864), mortality (OR 1.32, 95% CI 0.90-1.93, p = 0.152) or favourable outcome (OR 0.89, 95% CI 0.65-1.24, p = 0.507). Similar results were found for the different lipid variables: high LDL (OR 0.96, 95% CI 0.36-2.60, p = 0.942), high triglyceride (OR 1.74, 95% CI 0.84-3.56, p = 0.132) and low HDL (OR 1.78, 95% CI 0.68-4.65, p = 0.279) were not associated with increased odds for sICH. Likewise, neither mortality nor functional outcome at 3 months was significantly associated with any of the lipid variables in the univariable analysis following Bonferroni adjustment for multiple comparisons. The same results were found in the multivariable analysis adjusting for imbalances in baseline characteristics. Conclusions: In contrast to previous studies, we found that in stroke patients receiving thrombolysis therapy, neither the lipid profile nor prior statin use were associated with increased odds for sICH, functional outcome or mortality at 3 months.
Introduction
Intracerebral haemorrhage (ICH) is one of the most feared complications after thrombolytic therapy in stroke patients. Depending on the definition, it occurs in ap- proximately 6% of patients and is associated with a poor outcome [1] . Different factors, such as the presence of early hypodensity on CT, elevated serum glucose, history of diabetes, increased time to treatment, higher pre-treatment blood pressure, lower platelet count and history of cardiac disease, have been suggested as predictors of ICH after thrombolysis [2] .
However, the role of the lipid profile and prior statin use for the occurrence of symptomatic ICH (sICH) following intravenous thrombolysis and their implications for the outcome remain unclear. While the protective role of hydroxymethylglutaryl-CoA reductase inhibitors (statins) in first-ever and recurrent ischaemic strokes is clearly proven [3] , some authors also report statin use to be associated with favourable functional outcome following thrombolysis [4] , and others identified statin medication and low low-density lipoprotein (LDL) as risk factors for thrombolysis-related haemorrhages [5, 6] . However, the data remain controversial as some studies only identified high-admission triglyceride levels as a risk factor for sICH, but not LDL levels or statin therapy [7] . Finally, other authors report that the use of statins or hypercholesterolaemia before first-ever ischaemic stroke is associated with a better early outcome, while statin therapy may increase the risk of ICH [8] .
The present study aims to investigate the role of the lipid profile and statin use prior to intravenous thrombolytic therapy for acute ischaemic stroke patients in the occurrence of sICH based on our local thrombolysis database including 1,066 patients, employing two different definitions of ICH. Furthermore, the impact on functional outcome and mortality was assessed.
Methods

Patients
From 2001 to 2010 (cut-off point of the current analysis: 19 November 2010), all patients admitted to our hospital and undergoing intravenous thrombolysis for acute ischaemic stroke were included into an open, prospective database. Initial stroke severity was assessed using the National Institute of Health Stroke Scale (NIHSS) by a trained neurologist. Demographics, vascular risk factors, admission blood pressure, glucose levels, and previous medication including statin use were recorded. Lipid profiles were assessed as fasting values the morning following admission, including LDL, high-density lipoprotein (HDL), LDL/HDL ratio and triglyceride levels. Patients underwent a non-contrast brain CT scan before treatment and a routine brain CT scan 24-36 h after thrombolysis. Stroke subtypes were classified according to the TOAST classification: (1) large-artery atherosclerosis, (2) cardioembolism, (3) small-artery occlusion (lacunar), (4) stroke of other determined aetiology, and (5) stroke of undetermined aetiology [9] .
Outcome Parameters
Outcome parameters included the occurrence of sICH within 36 h following thrombolysis, the occurrence of any ICH, mortality at 3 months and functional outcome at 3 months. sICH was assessed using the slightly modified European Cooperative Acute Stroke Study (ECASS II) criteria (any haemorrhage with neurological deterioration, as indicated by an NIHSS score 6 4 points higher than the value at baseline, or any haemorrhage leading to death). Any ICH was defined as any blood on the follow-up CT scan within 36 h following thrombolysis. Functional outcome was assessed upon discharge and in the 90 days of follow-up and was measured by the modified Rankin scale (mRS) score. Favourable outcome was defined as an mRS score of 0-1.
Statistical Analysis
Baseline variables were compared using Pearson's 2 and the Mann-Whitney U tests where appropriate. For categorical variables, percentage proportions were calculated by dividing the number of events by the total number of patients, excluding missing or unknown cases. Analogously, median and interquartile ranges were calculated for continuous variables, leaving out missing or unknown cases.
Based on the literature [3] [4] [5] [6] [7] , low LDL levels, low HDL levels, high triglyceride levels and a high LDL/HDL ratio were considered risk factors for sICH, mortality and outcome. For further analyses, the population was thus grouped according to (1) statin use, (2) high versus low LDL levels, (3) high versus low HDL levels, (4) high versus low triglyceride levels, and (5) high versus low LDL/HDL ratio. For LDL, the cut-off of 100 mg/dl was chosen according to current guidelines [10] . Since no thresholds for HDL, triglycerides and the LDL/HDL ratio have been reported in the literature, the population was split using the 25th (for HDL) and 75th (for triglycerides and LDL/HDL ratio) percentiles as cut-off values. Odds ratios were calculated using 2 ! 2 cross-tables. Adjusted odds ratios were calculated using logistic regression models including age, gender, baseline NIHSS, hypertension, diabetes, atrial fibrillation, systolic and diastolic blood pressure, glucose level on admission, and stroke aetiology. All statistical analyses were performed using the SPSS software (version 16.0). Following Bonferroni adjustment for multiple comparisons, only p values ! 0.01 were considered significant.
Results
In total, 1,066 patients were registered in our local thrombolysis database. Baseline characteristics are listed in table 1 . sICH according to ECASS II criteria occurred in 57 patients (5.3%), while any ICH on the post-treatment CT scan was found in 186 patients (17.4%). Overall mortality at 3 months was 17.6% (188 patients). A favourable outcome (mRS 0-1) at 3 months was reached by 379 patients (35.6%). The number of patients with prior statin medication were equally distributed in patients with or without haemorrhages ( table 1 ). Likewise, there was no significant difference in median LDL, HDL or triglyceride levels and the LDL/HDL ratio between patients with or without ICH, regardless of the definition ( table 1 ) .
According to the literature, prior statin use, low LDL, low HDL and high triglyceride levels, as well as a high LDL/HDL ratio were defined as risk factors for sICH, mortality or unfavourable outcome. So far, no definite thresholds have been published. Therefore, in an exploratory approach, we defined low or high values according to the 25th and 75th percentiles in our population.
Prior Similar results were found for all lipid variables including low LDL ( ^ 100 mg/dl), low HDL ( ^ 36 mg/dl), high triglycerides ( 6 144 mg/dl) and high LDL/HDL ratios ( 6 3.33) ( table 2 ). Of note, the Bonferroni adjustment was applied to correct for multiple comparisons, and thus, only p values ! 0.01 were considered significant. Table 3 shows the multivariate analysis. As in the univariate analysis, after adjustment for baseline characteristics, neither prior statin use nor any of the lipid variables were associated with significantly increased odds for sICH, mortality or decreased odds for favourable functional outcome at 3 months. Although LDL levels below the 25th percentile were associated with a slightly increased risk of mortality (OR 1.82, 95% CI 1.01-3.29, p = 0.047), the result was not considered significant applying Bonferroni adjustment for multiple comparisons, requiring a p value ! 0.01.
Discussion
Based on our local thrombolysis database including a total of 1,066 patients, we found neither previous statin therapy nor the lipid profile to be associated with the oc- currence of thrombolysis-related ICH as described in previous studies [5] [6] [7] [11] [12] [13] , regardless of the definition used for ICH. The same was found for mortality or functional outcome at 3 months. These findings are in contrast to previous studies, which report concerning results about lipid profiles and statin use as risk factors for thrombolysis-related ICH (for an overview, see table 4 ).
Bang et al. [6] analyzed 104 patients receiving intravenous or intra-arterial thrombolysis with tissue plasminogen activator (tPA), including mechanical recanalization. In their study, lower LDL cholesterol levels upon admission but not prior statin use were found to be independently associated with sICH. In contrast, Uyttenboogaart et al. [7] including a population of 252 patients treated with intravenous tPA for acute ischaemic stroke only identified high triglyceride levels but not low LDL or prior statin as risk factors for sICH. Two other studies finally reported the use of lipid-lowering medication as an independent risk factor for sICH following thrombolysis [5, 12] .
In contrast to these studies -and in line with our results -the report of Montaner [14] showed a lack of association between previous statin use or the lipid profile with sICH among recombinant tPA-treated patients. However, the sample size was relatively small, including only lipid profiles -in contrast to other studies assessed in the hyperacute phase -from 60 patients; the results on prior statin use were based on 145 patients. Furthermore, a recent case-control study including 182 patients showed no significant difference in the incidence of sICH in patients with versus in those without statin pre-treatment (3.3 vs. 1.7%; p = 0.47) [15] . Likewise, there was no difference between the two groups with respect to favourable short-term (44.8 vs. 56%; p = 0.31) or long-term outcome (40 vs. 44.1%; p = 0.84). In contrast, in a meta-analysis provided in the same paper including 1,055 patients, statin pre-treatment was neither related to long-term functional outcome nor to mortality, but was shown to be a risk factor for sICH (OR 1.99, 95% CI 1.03-3.84, p = 0.04) [15] .
The heterogeneity in the previous studies may be due to several reasons. Firstly, they included a heterogeneous population undergoing different treatment modalities, including mechanical recanalization [6] and intra-arterial urokinase [5] . Second, all studies except for one [7] investigated only partial aspects, for instance providing data on statin use [8, 12] but not reporting lipid profiles, or providing data on sICH but not on functional outcomes [6, 8] . Furthermore, sample sizes in most of these Outcome parameters in the different subgroups Furthermore, with respect to sICH, the influence of the sICH definition has to be taken into account, since frequencies and risk factors may vary widely depending on the definition used [16] . In our study, lipid profiles or statin therapy were not associated with thrombolysis-related ICH, regardless of the definition used.
Our study included the so far largest population, providing data on lipid profiles, statin pre-treatment and different outcome parameters, but nevertheless has some limitations. Firstly, although the lipid profile was performed in a 12-to 24-hour fasting status, lipid levels in the acute phase of stroke may decrease. However, we aimed to determine the relation between admission lipid levels and prior statin use in acute thrombolyzed patients. Secondly, the retrospective character of our study and the non-blinded follow-up data collection could lead to a possible bias. Especially, since lipid profiles were not available for the entire population (LDL for 62.1%, HDL 62.9% and triglyceride 83.0%) and the baseline characteristics between those with versus those without LDL levels available differed significantly (see online suppl. table 1, www. karger.com/doi/10.1159/000335840). However, data on statin use were available for 95.5% of the population. Finally, data on pre-stroke mRS were not available, which may bias our outcome analysis since 17.9% of our patients had a history of previous stroke.
In summary, in contrast to previous studies, neither prior statin use nor the lipid profile were associated with sICH or any of the outcome parameters in patients undergoing thrombolysis for acute ischaemic stroke. An ongoing multi-centric, randomized, double-blind clinical trial now aims to evaluate the use of simvastatin in the acute phase of ischaemic stroke with respect to functional outcome and its association to haemorrhagic transformation [17] . This trial may help give a final answer to the question of statin use in patients undergoing thrombolysis for acute stroke.
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